PRAMOMOLECULAR's platform technology enables easy and efficient delivery of therapeutic oligonucleotides such as siRNAs or antisense DNAs to the lung, heart, pancreas and skin. This is of great therapeutic importance, as systemic delivery has so far only worked well in the liver.
PRAMOMOLECULAR is developing anticancer drugs to silence oncogenic RAS proteins in lung, pancreatic and skin cancer. In this process, we covalently couple a proprietary lipid-based delivery molecule to backbone-modified siRNA in the final step of fully automated oligonucleotide synthesis. We know of no simpler, more efficient delivery system for therapeutic oligonucleotides.
We are seeking development partners and investors for our preclinical and clinical developments, with which we aim to bring two drug candidates into the clinical phase by 2025.
PRAMOMOLECULAR is developing anticancer drugs to silence oncogenic RAS proteins in lung, pancreatic and skin cancer. In this process, we covalently couple a proprietary lipid-based delivery molecule to backbone-modified siRNA in the final step of fully automated oligonucleotide synthesis. We know of no simpler, more efficient delivery system for therapeutic oligonucleotides.
We are seeking development partners and investors for our preclinical and clinical developments, with which we aim to bring two drug candidates into the clinical phase by 2025.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Germany
Year Founded:
2021
Main Therapeutic Focus:
Oncology
Lead Product in Development:
NSCLC
Development Phase of Primary Product:
Discovery
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
